Printer Friendly

Innovus Pharma Launches OTC Hemorrhoid Xyralid Suppositories in Canada.

M2 PHARMA-February 1, 2019-Innovus Pharma Launches OTC Hemorrhoid Xyralid Suppositories in Canada

(C)2019 M2 COMMUNICATIONS

- US-based commercial-stage pharmaceutical company Innovus Pharmaceuticals, Inc. (OTCQB Venture Market: INNV) has launched its Xyralid Suppositories, for the reduction of swelling or inflammation of hemorrhoidal tissues and provides pain relief from burning, itching and discomfort, the company said.

Xyralid Suppositories received a Product License Application in Canada and the product is available as an over-the-counter or behind the counter drug and will not require a prescription.

The product is available in Canada directly through the company's website and through its Beyond Human marketing and sales platform.

Xyralid Suppositories are an FDA and Health Canada-OTC monograph compliant, fast-acting and powerful hemorrhoid suppository product. They contain the active ingredients cocoa butter and phenylephrine which provides fast relief for the pain and symptoms caused by hemorrhoids.

Hemorrhoids, also called "piles," are swollen and inflamed veins in the anus and lower rectum.

Hemorrhoids may result from straining during bowel movements or from the increased pressure on these veins during pregnancy, among other causes.

Hemorrhoids may be located inside the rectum (internal hemorrhoids) or they may develop under the skin around the anus (external hemorrhoids).

There are over 1.2m hemorrhoid sufferers in Canada, making it a very large market.

Headquartered in San Diego, Innovus Pharma is an emerging OTC consumer goods and specialty pharmaceutical company engaged in the commercialisation, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men's and women's health and vitality and respiratory diseases.

Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its OTC medicines and consumer and health products, which we market directly, commercial partners to primary care physicians, urologists, gynecologists and therapists, and directly to consumers through our on-line channels, retailers and wholesalers.

The company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application products.

The company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2019 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Geographic Code:1CANA
Date:Feb 1, 2019
Words:355
Previous Article:Co-Diagnostics to Raise USD 5.5m from Registered Direct Offering.
Next Article:Alexion, Caelum Biosciences Team to Develop Targeted Therapy for Light Chain Amyloidosis.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters